If your clinic offers exosome therapies, you are working in the highest-risk marketing space in regenerative medicine. The FDA has approved zero exosome products for human use. That single fact shapes everything you are allowed to say. This guide covers what that classification means for your marketing, the two mistakes clinics make, and the compliant language that still brings in inquiries.
TLDR: There are no FDA-approved exosome products for human use, and the FDA has issued public warnings about them. So you cannot market exosomes as an approved or effective treatment. But you do not have to go silent either. The safe path is education, teaching the science and your process without claiming an outcome. This guide covers what you can and cannot say, with a side-by-side copy table. None of this is legal advice. Run your copy past counsel.
Important Note
This article is for educational purposes only and does not constitute legal, medical, or regulatory advice. Marketing strategies discussed should be reviewed by qualified legal counsel before implementation, especially regarding FDA, FTC, and state-specific advertising regulations. Exosome marketing carries serious enforcement risk. Regen Portal is a marketing company, not a law firm or compliance consultancy.
Here is the anchor fact you cannot market around. As of 2026, the FDA has not approved any exosome product for any human medical use. The agency has said so plainly in its public consumer alert on regen products, and it has issued safety notifications and warning letters to companies selling them. This is not a gray area. It is the FDA’s stated position.
That fact puts exosome clinics in a hard spot. The treatment draws real patient interest, but the marketing rules are the strictest in the field. Say the wrong thing and you do not just risk an ad rejection. You risk an FDA letter or FTC action.
The good news is that “no approved products” does not mean “no marketing.” It means a specific kind of marketing: education, not claims. This guide walks through the FDA’s position, the two ways clinics get it wrong, and the compliant framework that lets you build inquiries without crossing a line.
The FDA’s Position Is The Non-Negotiable Starting Point
The FDA regulates exosome products and has approved none for human use. Any exosome product marketed as a treatment is, in the FDA’s view, an unapproved drug or biologic. That is the fact every marketing decision starts from.
The agency has been direct about it. Its consumer alert on regen products warns the public that exosome and stem cell products are often illegally marketed and have not been shown to be safe or effective for the uses claimed. You can read that warning on the FDA’s consumer alert on regen products page. The FDA has also issued public safety notifications and warning letters to exosome sellers.
For a marketer, the takeaway is simple. You cannot describe an exosome product as approved, proven, or effective for treating anything, because none are. The classification is settled, and your copy has to respect it.
What this means for your practice: Treat “no FDA-approved exosome products” as the fixed point your entire message is built around. Every claim you might want to make has to survive that fact first.
How The 361 Versus 351 Rule Applies To Exosomes
The FDA sorts human cell and tissue products into two lanes. A narrow set of low-risk products meets the criteria for lighter regulation. Everything else is treated as a drug or biologic that needs full FDA approval. Exosome products marketed for treatment fall in the second lane.
Exosomes used as a therapy do not meet the narrow criteria for the lighter lane. So the FDA treats them as unapproved biologics. Legal use means an FDA-authorized clinical trial, not a standard clinic service. Our explainer on the 361 versus 351 distinction every regen marketer needs breaks the two lanes down in plain terms.
This matters for marketing. As with all regen products, the FDA reads your ad language as evidence of intent. Market an exosome product as a treatment for a condition and you confirm it belongs in the drug lane. And there it has no approval.
What this means for your practice: Your marketing language is part of how the FDA classifies the product. Claiming an exosome treats a condition is not just a marketing risk. It is evidence of an unapproved drug claim.
Failure Mode One: Marketing As If Approved
The first mistake is the dangerous one. A clinic markets exosomes as an effective, available treatment, claiming results, naming conditions, implying approval. This draws exactly the FDA and FTC attention that ends in warning letters and enforcement.
This happens when a clinic treats exosomes like any other service and writes confident sales copy. “Exosome therapy for joint pain.” “Regenerate with exosomes.” “The future of healing, available now.” Every one of those implies a proven treatment. None exists in approved form. The FTC also requires real proof for health claims, and exosome claims cannot meet that bar.
The cost is severe. The FDA has sent warning letters to exosome sellers, and the FTC has pursued promoters of unproven regenerative treatments. This is not a theoretical risk. It is an active enforcement area.
What this means for your practice: Confident, claim-based exosome marketing is the single fastest way to draw enforcement. If your copy implies exosomes work for a condition, it is the wrong copy, no matter how well it converts.
Failure Mode Two: Going Completely Silent
The second mistake is quieter and more common. A clinic gets scared, decides exosomes are too risky to mention, and says nothing at all. The result is invisibility. Patients searching for information find competitors instead, and the clinic loses the inquiry.
Silence is an overcorrection. The rules do not forbid talking about exosomes. They forbid claiming they are approved or effective. There is a wide, safe space between bold claims and total silence. That space is where compliant marketing lives.
A clinic that goes dark also misses a trust chance. Honest content about what exosomes are, and what their status actually is, makes the clinic a trusted source. That is exactly what a cautious patient wants.
What this means for your practice: Silence is not safety. It is lost ground. You can market exosome education compliantly, and doing so builds more trust than either bold claims or an empty page.
The Compliant Framework: What You Can And Cannot Say
The compliant approach is education-only. You can teach the science, describe a process in neutral terms, and state credentials and FDA status honestly. You cannot claim efficacy, promise outcomes, or imply approval. The line is between teaching and claiming.
Here is the difference in practice, side by side.
| You Cannot Say | You Can Say |
|---|---|
| “Exosome therapy treats joint pain” | “Exosomes are extracellular vesicles studied for their role in cell communication” |
| “Regenerate damaged tissue with exosomes” | “Here is how the exosome research field describes these particles” |
| “FDA-approved exosome treatment” | “There are no FDA-approved exosome products; any use is investigational” |
| “Our patients see amazing results” | “Schedule a consult to discuss your situation and current options” |
| “The proven future of healing” | “Research into exosomes is ongoing, and the evidence remains limited” |
What You Can Say
You can publish explainers on exosome biology. You can describe what the research is exploring, with honest limits. You can state your providers’ credentials and explain your consult process. You can state the status plainly, which is itself useful, trust-building content. The FTC’s health products compliance guidance sets the standard for honest health claims, and teaching framing stays well inside it.
What You Cannot Say
You cannot claim or imply that exosomes treat, cure, or improve any condition. You cannot promise outcomes or share results that imply efficacy. You cannot call them approved, proven, or safe in absolute terms. And you cannot run a “book your exosome treatment” call to action, because that markets an unapproved product as a treatment.
What this means for your practice: Build every exosome page around teaching and consultation, never around outcomes. The honest version is the compliant version, and for a cautious patient it is also the more credible one.
Can You Run Google Or Meta Ads For Exosome Therapy?
Direct exosome ads are effectively off the table on the major platforms. Google’s health policy bans promotion of speculative and experimental treatments, which covers exosomes, and Meta applies its own health restrictions. So a “book exosome therapy” ad will not run.
What can run, in limited form, is genuinely teaching content, the same way it does for other restricted regen treatments. Our guides on Google Ads for regenerative medicine and whether you can run Facebook ads for PRP treatments cover how the educational route works on each platform. The same logic applies to exosomes, with even less room for error.
What this means for your practice: Do not plan a paid strategy around promoting exosome treatments directly. It will not run, and trying invites scrutiny. Educational content is the only viable paid angle, and even that needs careful framing.
A Compliant Exosome Service Page Structure
If you mention exosomes on your site at all, the page must be built as education, not a sales pitch. The safest structure describes the science, states the FDA status up front, explains your process, and invites a consult, with no efficacy language anywhere.
A compliant page covers what exosomes are in neutral scientific terms, states clearly that no exosome products are FDA-approved and that any use is investigational, describes your consultation process, and includes prominent disclaimers near the content. It avoids naming conditions exosomes “treat,” avoids outcome language, and avoids any booking call to action framed around the treatment itself. For how to structure compliant service pages generally, our guide on writing PRP service pages that rank and convert shows the pattern, which adapts directly to the stricter exosome context. Building this kind of compliant content is core to what we do in content creation.
What this means for your practice: An exosome page should read like an honest education resource with a clear regulatory disclosure, not a service offer. If it reads like a sales page, it is a liability.
Frequently Asked Questions
What can I say about exosome therapy in my marketing? You can teach the science, describe what research is exploring with honest limits, state your credentials and process, and state the FDA status plainly. You cannot claim or imply exosomes treat any condition, promise outcomes, or call them approved or proven. Education is safe. Claims are not.
Are exosome products approved by the FDA? No. As of 2026, the FDA has not approved any exosome product for any human medical use. The agency regulates therapeutic exosomes as unapproved drugs or biologics and has issued public warnings and warning letters about them.
How do I market exosome therapy without violating FDA rules? Market education, not treatment. Publish honest explainers on the science, state that no products are approved, describe your consultation process, and avoid all efficacy and outcome language. Never run a “book your exosome treatment” call to action.
What is the FDA’s position on exosome products in 2026? The FDA’s position is that there are no approved exosome products for human use, that therapeutic exosomes are unapproved biologics, and that many are illegally marketed. The agency’s consumer alert on regen products states this directly.
Can I run Google or Meta ads for exosome therapy? Not directly. Google bans promotion of speculative and experimental treatments, which covers exosomes, and Meta applies its own health restrictions. Only genuinely teaching content has any path, and even that requires careful, claim-free framing.
What are the FTC substantiation requirements for exosome marketing claims? The FTC requires competent and reliable scientific evidence before you make a health claim. Exosome efficacy claims cannot meet that bar, because the evidence and approvals do not exist. So any efficacy claim fails the FTC standard by default.
What does a compliant exosome service page look like? It describes the science neutrally, states up front that no exosome products are FDA-approved, explains your consultation process, includes prominent disclaimers, and contains no efficacy language or treatment-booking call to action. It reads as honest education, not a sales offer.
Key Takeaways
- No exosome products are FDA-approved. This is the fixed fact every marketing decision starts from.
- Your language is evidence. Marketing exosomes as a treatment confirms an unapproved drug claim to the FDA.
- Bold claims invite enforcement. The FDA and FTC actively pursue exosome efficacy claims.
- Silence is not the answer either. Going dark loses inquiries and a trust chance.
- Education is the safe path. Teach the science and your process, state the status honestly, claim no outcomes.
- Direct ads will not run. Google and Meta block promotion of exosome treatments; only education has a path.
- Build pages as education. State the FDA status up front and skip all efficacy language.
PS: Build Exosome Content That Stays Safe
PS: Exosome marketing is the tightest rope in regen medicine, and the difference between a trust-building page and an enforcement risk is the framing. If you want help building exosome content that brings in inquiries without crossing a line, it is what we do for regen practices. Reach out at [email protected], or watch how we approach compliant regen marketing on YouTube and subscribe for weekly insights.
About Regen Portal
Regen Portal is a marketing company serving the regenerative medicine industry. We provide SEO, content creation, social media management, paid advertising, website development, and branding services for clinics, manufacturers, distributors, and independent providers. Some strategies discussed in our educational content align with services we offer. For more on how we work, contact us.
Oscar Tellez is the founder of Regen Portal, a marketing company built for the regenerative medicine industry. With over 15 years of experience spanning clinical operations, product distribution, and digital marketing, Oscar has helped hundreds of practices, manufacturers, and distributors grow through compliant, high-performance marketing strategies. He holds a B.S. in Exercise Physiology and Health Promotion from Florida Atlantic University.
